Harmony Biosciences Holdings (HRMY) Long-Term Investments (2022 - 2026)

Harmony Biosciences Holdings has disclosed Long-Term Investments across 5 years of filings, most recently posting $229.6 million for Q1 2026.

• Long-Term Investments for Q1 2026 came in at $229.6 million, up 122.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $229.6 million (up 122.34% YoY), and the FY2025 annual result was $107.1 million, down 1.6% from the prior year.
• Long-Term Investments came in at $229.6 million for Q1 2026 at Harmony Biosciences Holdings, up from $107.1 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $229.6 million in Q1 2026 to a low of $4.7 million in Q2 2022.
• The 5-year median for Long-Term Investments is $84.2 million (2024), against an average of $81.7 million.
• Across the five-year window, Long-Term Investments surged 1135.54% in 2023 and declined 1.6% in 2025, its largest moves.
• Harmony Biosciences Holdings' Long-Term Investments stood at $22.6 million in 2022, then surged by 219.78% to $72.2 million in 2023, then jumped by 50.86% to $108.9 million in 2024, then declined by 1.6% to $107.1 million in 2025, then soared by 114.28% to $229.6 million in 2026.
• The last three Long-Term Investments figures came in at $229.6 million (Q1 2026), $107.1 million (Q4 2025), and $105.8 million (Q3 2025), per Business Quant data.